Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

Action is the latest following Baldwin’s investigation into the extremely high prices these companies charge for inhalers ...

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...

At least 29 patent suits were filed in the District of New Jersey in November, reflecting a jump from the rate of 18 suits ...

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...